<DOC>
	<DOCNO>NCT01473095</DOCNO>
	<brief_summary>This open-label , Phase 1 , dose escalation study oral ARQ 092 administer subject advance solid tumor recurrent malignant lymphoma . The study design explore safety , tolerability , pharmacokinetics , pharmacodynamics ARQ 092 define recommend Phase 2 dose ARQ 092 .</brief_summary>
	<brief_title>Phase 1 Dose Escalation Study ARQ 092 Adult Subjects With Advanced Solid Tumors Recurrent Malignant Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Men woman ≥18 year old 2 . Histologically cytologically document , incurable , locally advanced metastatic solid tumor recurrent malignant lymphoma subject fail standard therapy standard curative therapy exist tolerable . 3 . Evaluable measurable disease 4 . Life expectancy great three month 5 . ECOG performance status ≤2 6 . Hemoglobin ( Hgb ) ≥9.5 g/dl 7 . Absolute neutrophil count ( ANC ) ≥1.5 x 10^9/L 8 . Platelet count ≥75 x 10^9/L 9 . Total bilirubin ≤1.5 × upper limit normal ( ULN ) 10 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤3 × ULN 11 . Serum creatinine ≤1.5 x ULN creatinine clearance &gt; 60 mL/min/1.73 m^2 subject creatinine level &gt; 1.5 x ULN 12 . Agree use doublebarrier contraceptive measure avoid intercourse study 90 day last dose study drug 1 . History Type 1 2 diabetes mellitus require regular medication ( metformin oral hypoglycemic agent ) fast glucose ≥160 mg/dL prestudy visit . If diabetic cohort enrol , subject medical history control Type 1 2 diabetes mellitus enrol cohort . 2 . Grade 2 bad hypercholesterolemia hypertriglyceridemia &gt; 8 % glycated Hb ( HbA1C ) 3 . Malabsorption syndrome 4 . Known brain metastasis radiographically stable ≥3 month leptomeningeal disease 5 . History myocardial infarction ( MI ) NYHA Class IIIV congestive heart failure within 6 month administration first dose ARQ 092 ( MI occur &gt; 6 month first dose ARQ 092 permit ) ; Grade 2 bad conduction defect ( eg right leave bundle branch block ) ; leave ventricular ejection fraction ( LVEF ) &lt; 50 % assessed echocardiogram/MUGA scan 6 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first dose ARQ 092 ( within 2 week orally administer drug ) 7 . Major surgery within four week first dose ARQ 092 8 . Previous treatment AKT inhibitor 9 . Concurrent severe uncontrolled illness relate cancer 10 . Ongoing active know infection , include human immunodeficiency virus ( HIV ) infection bleed 11 . Psychiatric illness/substance abuse/social situation would limit compliance study requirement . 12 . Blood transfusion within 5 day prior blood draw use confirm eligibility 13 . Pregnant breastfeed 14 . Previous malignancy within 2 year prior first dose ARQ 092 , exception carcinoma insitu cervix , basal cell carcinoma superficial bladder tumor curatively treat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AKT</keyword>
	<keyword>ARQ 092</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Molecular therapy</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Phase I</keyword>
	<keyword>Endometrial cancer</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>AKT pathway</keyword>
	<keyword>AKT signal</keyword>
	<keyword>AKT inhibitor</keyword>
	<keyword>AKT pan inhibitor</keyword>
	<keyword>AKT1</keyword>
	<keyword>AKT2</keyword>
	<keyword>AKT3</keyword>
	<keyword>AKT1 mutation</keyword>
	<keyword>AKT1-E17K</keyword>
	<keyword>AKT1-E17K mutation</keyword>
	<keyword>AKT 2 inhibitor</keyword>
	<keyword>AKT 3 inhibitor</keyword>
	<keyword>AKT 3 amplification</keyword>
	<keyword>PI3K AKT mTOR signal pathway</keyword>
	<keyword>mTOR inhibitor</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>Clinical oncology</keyword>
	<keyword>Tumor</keyword>
	<keyword>Tumour</keyword>
	<keyword>PIK3CA H1047R mutation</keyword>
</DOC>